CA2253869C - Substituted oxobutyric acids as matrix metalloprotease inhibitors - Google Patents

Substituted oxobutyric acids as matrix metalloprotease inhibitors Download PDF

Info

Publication number
CA2253869C
CA2253869C CA002253869A CA2253869A CA2253869C CA 2253869 C CA2253869 C CA 2253869C CA 002253869 A CA002253869 A CA 002253869A CA 2253869 A CA2253869 A CA 2253869A CA 2253869 C CA2253869 C CA 2253869C
Authority
CA
Canada
Prior art keywords
carbons
alpha
mmp
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002253869A
Other languages
English (en)
French (fr)
Other versions
CA2253869A1 (en
Inventor
Brian R. Dixon
Jinshan Chen
Michael Van Zandt
David R. Brittelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2253869A1 publication Critical patent/CA2253869A1/en
Application granted granted Critical
Publication of CA2253869C publication Critical patent/CA2253869C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
CA002253869A 1996-05-15 1997-05-12 Substituted oxobutyric acids as matrix metalloprotease inhibitors Expired - Fee Related CA2253869C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15
US08/648,384 1996-05-15
PCT/US1997/007975 WO1997043238A1 (en) 1996-05-15 1997-05-12 Substituted oxobutyric acids as matrix metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
CA2253869A1 CA2253869A1 (en) 1997-11-20
CA2253869C true CA2253869C (en) 2003-04-22

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253869A Expired - Fee Related CA2253869C (en) 1996-05-15 1997-05-12 Substituted oxobutyric acids as matrix metalloprotease inhibitors

Country Status (18)

Country Link
EP (1) EP0912487A1 (zh)
JP (1) JP3417951B2 (zh)
CN (1) CN1163466C (zh)
AR (1) AR007096A1 (zh)
AU (1) AU727648B2 (zh)
CA (1) CA2253869C (zh)
CO (1) CO4990925A1 (zh)
HR (1) HRP970246B1 (zh)
ID (1) ID20291A (zh)
MY (1) MY132470A (zh)
PA (1) PA8429401A1 (zh)
PE (1) PE65998A1 (zh)
SV (1) SV1997000034A (zh)
TN (1) TNSN97085A1 (zh)
TW (1) TW467892B (zh)
WO (1) WO1997043238A1 (zh)
YU (1) YU18797A (zh)
ZA (1) ZA974032B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
JP2017511319A (ja) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト キラル２，５−ジ置換されたシクロペンタンカルボン酸誘導体およびそれの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제

Also Published As

Publication number Publication date
ZA974032B (en) 1998-02-19
WO1997043238A1 (en) 1997-11-20
MY132470A (en) 2007-10-31
CN1225622A (zh) 1999-08-11
AU3121997A (en) 1997-12-05
JP3417951B2 (ja) 2003-06-16
AR007096A1 (es) 1999-10-13
SV1997000034A (es) 1999-07-05
PA8429401A1 (es) 2000-05-24
CA2253869A1 (en) 1997-11-20
CN1163466C (zh) 2004-08-25
AU727648B2 (en) 2000-12-21
TW467892B (en) 2001-12-11
CO4990925A1 (es) 2000-12-26
EP0912487A1 (en) 1999-05-06
PE65998A1 (es) 1998-10-20
ID20291A (id) 1998-11-19
HRP970246A2 (en) 1998-04-30
TNSN97085A1 (fr) 2005-03-15
YU18797A (en) 1999-11-22
JPH11509870A (ja) 1999-08-31
HRP970246B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
US20050267102A1 (en) Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
AU714207B2 (en) Inhibition of matrix metalloproteases by 2-substituted-4- (4-substitutedphenyl)-4-oxobutyric acids
EP0937036B1 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
WO1997043239A9 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
CA2253869C (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
US5968795A (en) Biaryl acetylenes as inhibitors of matrix metalloproteases
CA2253796C (en) Inhibition of matrix metalloproteases by acetylene containing compounds
US5863915A (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
AU727899B2 (en) Inhibition of matrix metalloproteases by substituted phenalkyl compounds
CA2253795C (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
US5932577A (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
WO1997043238A9 (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
AU715877B2 (en) Inhibition of matrix metalloproteases by 2-(omega- aroylalkyl)-4-biaryl-oxobutyric acids
US5804581A (en) Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US5932763A (en) Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed